TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03791645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sky Intervention
Description: SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (\~3 hours/day), followed by 4 weekly follow-ups (\~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
Study: NCT01313806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator
Description: Treatment group vs. Placebo group

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Resonator Device
Study: NCT01062620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXL1717
Description: Phase I study with increasing dosage and treatment duration
Study: NCT02932189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
Study: NCT01354353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Administered orally
Study: NCT06011330

Intervention type: DRUG
Intervention: Fruquintinib combined with anti-PD-1 antibodies
Description: Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
Study: NCT01022567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendicectomy
Description: Standard appendicectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
Study: NCT04348591

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Restructuring
Description: All participants will learn how to change their thinking in order to be less upset when confronted with stressors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: All participants will learn how to change their thinking in order to be less upset when confronted with stressors
Study: NCT00320606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression Withdrawal
Description: Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
Study: NCT03984825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Portia
Description: Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
Study: NCT02478151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrganOx Metra
Description: Normothermic machine perfusion (NMP) Metra device
Study: NCT04348591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neurostimulation
Description: all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurostimulation
Description: all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette
Study: NCT03754062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Administration of Placebo by pill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Administration of L-dopa by pill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Administration of Haloperidol by pill.
Study: NCT05004142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c+Fulvestrant
Description: FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c+Letrozole+Goserelin
Description: FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
Study: NCT03102359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Helmet
Description: Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Helmet
Description: Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
Study: NCT01836744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Survival rate dental implant (OsseoSpeed™)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Survival rate dental implant (OsseoSpeed™)
Study: NCT04466501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACR LAB
Description: The ACR \| LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
Study: NCT04109235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training Physical Activity (PA) Advice
Description: This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Population-Based Physical Activity (PA) Advice
Description: This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
Study: NCT03159377

Intervention type: DEVICE
Intervention: Ultra low dose chest CT
Description: Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
Study: NCT00948662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-760
Description: SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of SAM-760
Description: SAM-760 matching placebo capsule, single dose, 1 day,

Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole
Description: Ketoconazole oral tablets, 200 mg bid, 14 days
Study: NCT00242385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor
Description: Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose of 60 mg/kg alpha1-proteinase inhibitor
Description: Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
Study: NCT04552379

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon beta-1a
Description: Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at \~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use.
Study: NCT04980924

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03858062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy (with or without glucose sensor)
Description: Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas (Inreda Diabetic)
Description: Bi-hormonal reactive closed loop system without mealtime announcement
Study: NCT02871115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy Intervention
Description: Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
Study: NCT02862821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HR-EEG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HR-EEG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HR-EEG
Study: NCT01553916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Study: NCT03308981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REThink therapeutic online game
Description: The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REBE group
Description: In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
Study: NCT05753280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients take 800 mg vitamin D capsules daily during the whole treatment period
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine
Study: NCT01982773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Hope Box Smartphone App
Description: Smartphone app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Printed materials
Study: NCT02263482

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate-intensity group
Description: Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity group
Description: Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
Study: NCT03850327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOMONITOR III
Description: Patients with ICM indication receive a third-generation implantable cardiac monitor
Study: NCT03936517

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
Study: NCT02332811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer carbonate 800mg
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer carbonate 800mg
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer carbonate 2.4 g
Description: Pharmaceutical form:powder~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer carbonate 2.4 g
Description: Pharmaceutical form:powder~Route of administration: oral
Study: NCT02803385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continous Epidural Analgesia
Description: continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Epidural Analgesia
Description: patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
Study: NCT04161664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: 6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
Study: NCT01818713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-101
Description: 50 mg/m2 2B3-101 intravenous 3-weekly administration
Study: NCT05049538

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Intervention: Liquid Biopsy
Description: Undergo liquid biopsy
Study: NCT02141009

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevnar 13
Study: NCT05049538

Intervention type: OTHER
Intervention: Pap Smear
Description: Undergo Pap smear
Study: NCT04510454

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR
Description: Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
Study: NCT03548129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphomycin
Description: Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Culture specific antibiotic therapy
Description: Culture-specific antibiotic treatment for 5 days
Study: NCT02176590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power PATH
Description: PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
Study: NCT04737382

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ctDAN analysis
Description: ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
Study: NCT01390805

Intervention type: DRUG
Intervention: Valaciclovir Hydrochloride.
Study: NCT02176590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head Start as usual
Description: Standard Head Start programming (including classroom instruction, meals, and family services)
Study: NCT04515043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.
Description: blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine